Healthcare Industry News: reprocessing
News Release - December 8, 2010
Bausch + Lomb Storz(R) Ophthalmics Introduces a New Line of Single-Use Cataract InstrumentsALISO VIEJO, CA--(Healthcare Sales & Marketing Network) - Bausch + Lomb Storz® Ophthalmic Instruments has launched a new line of single-use cataract instrumentation in the United States. The line includes six microsurgical forceps and three cataract surgery manipulators to expand on the Bausch + Lomb Storz® Ophthalmics premium, high-quality cataract instrument line.
These single-use instruments are designed to provide safety, consistency and convenience by reducing the risk of infection and cross-contamination, eliminating time and cost associated with reprocessing reusable instruments.
The line includes six forceps that are sold eight per box. The available designs include: a Capsulorhexis Forceps, a Bonn Forceps, a Tying Forceps, a McPherson Tying Forceps, a Pierse Tying Forceps and a MICS™ Capsulorhexis Forceps.
Three manipulators are also included in the line and are packaged twelve per box. Manipulator designs include: a Koch Stop & Chop Manipulator, a Phaco Spatula and a Sinskey Hook.
For more information, to request a quote, or to place an order online, visit the Storz® Ophthalmic Instruments web site at www.storzeye.com/sucataract.aspx. Contact Bausch + Lomb customer service at 1-800-338-2020 from 8:00 a.m. to 8:00 p.m. EST.
About Bausch + Lomb
Bausch + Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch + Lomb name is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.
STORZ® is a trademark of Bausch & Lomb Incorporated.
Source: Bausch & Lomb
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBausch & Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE(TM) Clinical Decision Support Software
Bausch & Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
FDA Approves Bausch & Lomb ClearVisc(TM) Dispersive Ophthalmic Viscosurgical Device